What is Amagma?
Amagma is a clinical-stage biotechnology company dedicated to pioneering first-in-class therapeutics for immune and inflammatory conditions. Leveraging a genetics-informed approach and advanced antibody engineering, the company targets the root causes of diseases like atopic dermatitis. Their innovative strategy aims to redefine treatment paradigms for patients struggling with uncontrolled symptoms, positioning Amagma at the forefront of biological innovation in the therapeutic landscape.
How much funding has Amagma raised?
Amagma has raised a total of $16.5M across 1 funding round:
Other Financing Round
$16.5M
Other Financing Round (2020): $16.5M, investors not publicly disclosed
What's next for Amagma?
The recent major strategic investment provides Amagma with substantial backing to advance its pipeline and scale its operations. This capital infusion is expected to accelerate the development of their novel antibody engineering platform and clinical trials, particularly for atopic dermatitis. The company's focus on addressing underlying disease mechanisms suggests a strong potential for market disruption and significant growth in the competitive biotech sector.
See full Amagma company page
